X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare, Analyse Unichem Lab with ADCOCK INGRAM HOLDINGS LTD. - S. Africa - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs ADCOCK INGRAM (S. Africa) - Comparison Results

ADCOCK INGRAM (S. Africa)
   Change

Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 UNICHEM LAB   ADCOCK INGRAM
EQUITY SHARE DATA
    UNICHEM LAB
Mar-16
ADCOCK INGRAM
Jun-14
UNICHEM LAB/
ADCOCK INGRAM
5-Yr Chart
Click to enlarge
High Rs334399-   
Low Rs174288-   
Sales per share (Unadj.) Rs146.9118.8-  
Earnings per share (Unadj.) Rs11.9-29.9-  
Cash flow per share (Unadj.) Rs16.2-24.8-  
Dividends per share (Unadj.) Rs2.000-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs105.193.3-  
Shares outstanding (eoy) m90.84168.78-   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x1.72.9 59.8%   
Avg P/E ratio x21.4-11.5 -186.0%  
P/CF ratio (eoy) x15.7-13.9 -113.3%  
Price / Book Value ratio x2.43.7 65.6%  
Dividend payout %16.80-   
Avg Mkt Cap Rs m23,07358,031 39.8%   
No. of employees `0005.74.3 132.1%   
Total wages/salary Rs m2,5583,642 70.2%   
Avg. sales/employee Rs Th2,352.54,671.9 50.4%   
Avg. wages/employee Rs Th450.9848.4 53.1%   
Avg. net profit/employee Rs Th190.4-1,177.2 -16.2%   
INCOME DATA
Net Sales Rs m13,34620,056 66.5%  
Other income Rs m192140 136.6%   
Total revenues Rs m13,53820,197 67.0%   
Gross profit Rs m1,639-3,476 -47.2%  
Depreciation Rs m390866 45.1%   
Interest Rs m29543 5.3%   
Profit before tax Rs m1,412-4,744 -29.8%   
Minority Interest Rs m0-13 0.0%   
Prior Period Items Rs m-40-   
Extraordinary Inc (Exp) Rs m-350-   
Tax Rs m293296 98.7%   
Profit after tax Rs m1,080-5,054 -21.4%  
Gross profit margin %12.3-17.3 -70.9%  
Effective tax rate %20.7-6.2 -331.7%   
Net profit margin %8.1-25.2 -32.1%  
BALANCE SHEET DATA
Current assets Rs m5,97914,690 40.7%   
Current liabilities Rs m2,4328,265 29.4%   
Net working cap to sales %26.632.0 83.0%  
Current ratio x2.51.8 138.3%  
Inventory Days Days63111 56.9%  
Debtors Days Days60124 48.7%  
Net fixed assets Rs m6,4038,563 74.8%   
Share capital Rs m18293 195.1%   
"Free" reserves Rs m9,2930-   
Net worth Rs m9,54815,742 60.7%   
Long term debt Rs m2305,532 4.2%   
Total assets Rs m12,84329,738 43.2%  
Interest coverage x50.0-7.7 -647.0%   
Debt to equity ratio x00.4 6.9%  
Sales to assets ratio x1.00.7 154.1%   
Return on assets %8.6-15.2 -56.9%  
Return on equity %11.3-32.1 -35.2%  
Return on capital %14.3-19.8 -72.4%  
Exports to sales %29.20-   
Imports to sales %6.30-   
Net fx Rs m3,1940-   
CASH FLOW
From Operations Rs m1,1191,712 65.4%  
From Investments Rs m-853-526 162.3%  
From Financial Activity Rs m-3345,021 -6.7%  
Net Cashflow Rs m-686,207 -1.1%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ADCOCK INGRAM (S. Africa) is South Africa Rand. All data has been converted at 5.51 Rs / ZAR

Compare UNICHEM LAB With: ACTAVIS (US)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare UNICHEM LAB With: MERCK LTD  BIOCON LTD  WOCKHARDT LTD.  DISHMAN PHARMA  IPCA LABS  



Today's Market

Global Stock Markets Rebound After Sharp Weekly Drop(RoundUp)

Global financial markets rallied this week and brushed aside a rise in global borrowing costs while the dollar hit its lowest level since 2014.

Related Views On News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Here's What You Should Do in this Market Crash(The 5 Minute Wrapup)

Feb 6, 2018

The market correction has provided a golden opportunity to buy five high-quality safe stocks.

As the Market Corrects... It's Time to Buy More(Smart Contrarian)

Feb 5, 2018

The recent sell off in the stock market offers buying opportunity in some quality small caps.

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

When Small is Not Always Beautiful(Chart Of The Day)

Feb 6, 2018

Big companies enjoying tax deductions and exemptions have an edge over the small companies.

What Should Mutual Fund Investors Do After LTCG Tax Norms(Outside View)

Feb 6, 2018

PersonalFN explain what investors should after LTCG tax norms.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Feb 16, 2018 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB 8-QTR ANALYSIS

COMPARE UNICHEM LAB WITH

MARKET STATS